According to a post on the FDA’s website, Juno Therapeutics’ treatment of multiple myeloma was granted FDA orphan designation. Juno Therapeutics is a Bristol-Myers Squibb Company.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BMY:
- Bristol-Myers sues, calls Inflation Reduction Act provisions ‘unconstitutional’
- Bristol-Myers announces primary analysis results from TRANSCEND trials
- Bristol Myers Squibb (NYSE:BMY) Joins Quest to Prevent Fed’s Price Negotiations
- FDA approves sNDA for Bristol-Myers’ phase 3 VALOR-HCM study of CAMZYOS
- Don’t Forget About Cyclical Value. 3 Stocks to Consider